Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products for the treatment of asthma; and naloxone injection for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, and injectables; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.
Wall Street Analysts Forecast Growth
Separately, StockNews.com started coverage on shares of Adamis Pharmaceuticals in a research report on Sunday, August 14th. They set a "hold" rating on the stock.
Adamis Pharmaceuticals Price Performance
Shares of ADMP traded down $0.01 during trading hours on Friday, hitting $0.33. The company had a trading volume of 697,581 shares, compared to its average volume of 1,083,751. The business has a fifty day moving average of $0.42 and a 200-day moving average of $0.49. Adamis Pharmaceuticals has a 12 month low of $0.31 and a 12 month high of $1.48.
Adamis Pharmaceuticals (NASDAQ:ADMP - Get Rating) last issued its quarterly earnings data on Wednesday, August 10th. The specialty pharmaceutical company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.02). The firm had revenue of $0.04 million for the quarter, compared to the consensus estimate of $1.02 million. Equities analysts forecast that Adamis Pharmaceuticals will post -0.15 EPS for the current year.